Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 18, 2024 (filed on Apr 18, 2024)Insider Name:Baker Bros. Advisors LpOwnership Type:Indirect OwnershipSecurities:Non-Voting Ordinary SharesNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 18, 2024 (filed on Apr 18, 2024)Insider Name:Baker Bros. Advisors LpOwnership Type:Indirect OwnershipSecurities:Non-Voting Ordinary SharesNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 18, 2024 (filed on Apr 18, 2024)Insider Name:Baker Bros. Advisors LpOwnership Type:Indirect OwnershipSecurities:American Depositary SharesNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 18, 2024 (filed on Apr 18, 2024)Insider Name:Baker Bros. Advisors LpOwnership Type:Indirect OwnershipSecurities:American Depositary SharesNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 11, 2024 (filed on Apr 12, 2024)Insider Name:Hannay Michael Charles FergusonOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-257Price:$22.49
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Lee KevinOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,158Price:$23.81
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Skynner MichaelOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-955Price:$23.81
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Milnes AlistairOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-955Price:$23.81
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Crockett NigelOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-955Price:$23.81
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Keen NicholasOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-790Price:$23.81
Filings by filing date
-
Apr 18, 2024 (filed on Apr 18, 2024)Insider Name:Baker Bros. Advisors LpOwnership Type:Indirect OwnershipSecurities:Non-Voting Ordinary SharesNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 18, 2024 (filed on Apr 18, 2024)Insider Name:Baker Bros. Advisors LpOwnership Type:Indirect OwnershipSecurities:Non-Voting Ordinary SharesNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 18, 2024 (filed on Apr 18, 2024)Insider Name:Baker Bros. Advisors LpOwnership Type:Indirect OwnershipSecurities:American Depositary SharesNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 18, 2024 (filed on Apr 18, 2024)Insider Name:Baker Bros. Advisors LpOwnership Type:Indirect OwnershipSecurities:American Depositary SharesNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 11, 2024 (filed on Apr 12, 2024)Insider Name:Hannay Michael Charles FergusonOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-257Price:$22.49
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Lee KevinOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,158Price:$23.81
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Skynner MichaelOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-955Price:$23.81
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Milnes AlistairOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-955Price:$23.81
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Crockett NigelOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-955Price:$23.81
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Keen NicholasOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-790Price:$23.81
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Babraham Hall CAMBRIDGE CB21 6GS |
Tel: | N/A |
Website: | https://www.bicycletherapeutics.com |
IR: | See website |
Key People | ||
Kevin Lee Chief Executive Officer, Executive Director | Alethia R. Young Chief Financial Officer, Principal Financial Officer | Alistair Milnes Chief Operating Officer |
Michael Skynner Chief Technology Officer | Travis Thompson Chief Accounting Officer, Principal Accounting Officer | Nicholas Keen Chief Scientific Officer |
Santiago Arroyo Chief Development Officer | Nigel Crockett Chief Business Officer |
Business Overview |
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio. |
Financial Overview |
For the fiscal year ended 31 December 2023, Bicycle Therapeutics PLC (ADR) revenues increased 87% to $27M. Net loss increased 60% to $180.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing va increase of 98% to $140.9M (expense), General and administrative - Balancing increase of 29% to $24M (expense). |
Employees: | 284 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $434.10M as of Dec 31, 2023 |
Annual revenue (TTM): | $26.98M as of Dec 31, 2023 |
EBITDA (TTM): | -$182.80M as of Dec 31, 2023 |
Net annual income (TTM): | -$180.66M as of Dec 31, 2023 |
Free cash flow (TTM): | -$63.56M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 42,586,185 as of Feb 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |